SAB Biotherapeutics(SABS) - 2023 Q4 - Annual Results

FORM 8-K Filing Details This section details the registrant's identity, contact information, and securities filing status Registrant Information This section provides the core identification details for SAB Biotherapeutics, Inc. as the registrant, including its legal name, jurisdiction of incorporation, and primary contact information - Registrant Name: SAB BIOTHERAPEUTICS, INC.[2] - Jurisdiction of Incorporation: Delaware[2] - Principal Executive Offices: 2100 East 54th Street North, Sioux Falls, South Dakota 57104[2] - Registrant's Telephone Number: 605 679-6980[2] Securities and Filing Status This section outlines the company's registered securities and confirms its status as an emerging growth company, indicating specific regulatory considerations Registered Securities | Title of each class | Symbol(s) | Name of each exchange on which registered | | :------------------ | :-------- | :---------------------------------------- | | Common stock, $0.0001 par value per share | SABS | The Nasdaq Stock Market LLC | | Warrants, each exercisable for one share of Common Stock | SABSW | The Nasdaq Stock Market LLC | - SAB Biotherapeutics, Inc. is an Emerging Growth Company[5] - The registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards[6] Current Report Items This section details the company's financial results announcement and lists accompanying exhibits Item 2.02 Results of Operations and Financial Condition SAB Biotherapeutics, Inc. issued a press release on March 29, 2024, to announce its financial results for the year and quarter ended December 31, 2023, along with a corporate update. This press release is furnished as Exhibit 99.1 - Date of Report: March 29, 2024[2] - Press Release Date: March 29, 2024[7] - Content of Press Release: Financial results for the year and quarter ended December 31, 2023, and a corporate update[7] - Exhibit Reference: The press release is furnished as Exhibit 99.1[7] - Filing Status: The information in this item, including Exhibit 99.1, is furnished and not deemed 'filed' for Section 18 of the Exchange Act[8] Item 9.01 Financial Statements and Exhibits This section lists the exhibits accompanying the Form 8-K filing, which include the press release detailing financial results and the interactive data file for the cover page Exhibits Filed | Exhibit Number | Description | | :------------- | :----------------------------------------------------------------------- | | 99.1 | Press Release of the Company, dated March 29, 2024 | | 104 | Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document. | SIGNATURES This section confirms the official signing of the Form 8-K report by the authorized executive Report Signatures The Form 8-K report was duly signed on behalf of SAB Biotherapeutics, Inc. by its Chief Executive Officer, Samuel J. Reich, on March 29, 2024 - Signatory: Samuel J. Reich[13] - Title: Chief Executive Officer[13] - Date of Signature: March 29, 2024[13]